Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Akebia Therapeutics (NQ: AKBA )

3.110 USD -0.200 (-6.04%)
Official Closing Price Updated: 6:33 PM EST, Dec 1, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,056,614
Open 3.370
Bid (Size) 3.110 (7)
Ask (Size) 3.120 (69)
Prev. Close 3.310
Today's Range 3.100 - 3.370
52wk Range 2.090 - 13.71
Shares Outstanding 56,913,886
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will participate in the Piper... 
From PR Newswire
Top Penny Stocks To Watch Today; 4 With 75%-233% Price Targets
From Penny Stocks to Buy, Picks, News and Information | PennyStocks.com - Feed

Performance

YTD
-50.95%
-50.95%
1 Month
+34.63%
+34.63%
3 Month
-70.12%
-70.12%
6 Month
-72.16%
-72.16%
1 Year
-41.54%
-41.54%

More News

Read More
Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™
From PR Newswire
Akebia Announces Manuscript Highlighting Global Phase 3 INNO2VATE Program Rationale, Study Design and Baseline Characteristics Published in Peer-Reviewed Medical Journal
From PR Newswire
5 Best Penny Stocks Today If Biotech Stocks Are Your Focus
From Penny Stocks to Buy, Picks, News and Information | PennyStocks.com - Feed
Akebia Reports Third Quarter 2020 Financial Results and Recent Business Updates
From PR Newswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From PR Newswire
Akebia Therapeutics to Report Third Quarter 2020 Financial Results and Discuss Recent Business Highlights
From PR Newswire
Akebia Presents Results from its PRO2TECT Global Phase 3 Program of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients Not on Dialysis During Late-Breaking Session
From PR Newswire
68 Biggest Movers From Yesterday
Tags FUV MGNI MDGS
From Benzinga
44 Stocks Moving In Thursday's Mid-Day Session
Tags GCI CIIC XYF
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.